RESHAPE LIFESCINCESES® announces a $ 6.0 million general offer – Lifesciences (NASDAQ: RSLS)

Irvin, California, February 15, 2025 (Globe Neuws) – Lifesciences^® (“” Reshape “or” The Company “) Rssfor Today, the first company led by doctors led by doctors and health solutions today announced its public offer of 2575107 units at a general offer price of $ 2.33 per unit. Each unit consists of one shared share (or a pre -financing order to buy one shared share in Lieu) and one note to buy one common share.

The notes, whose exercises can only be practiced if the shareholders approved by them, will be practiced at the beginning at a price of $ 5.83 per share, taking into account the standard adjustments to profits, splits and similar events, and also subject to control when re -setting once on the date of re -control ( As shown in orders), according to the price of the floor described in it. Orders on a non -cash alternative can also be practiced in an alternative that the pregnant woman can exchange each note by 1.2 times the number of regular shares that they will receive at a cash exercise. Exercise orders after submitting the notice regarding the approval of the shares holder will be expired and their validity will end later in (1) twelve (12) days from the date of the approval of the shareholder and (2) earlier in (S) the date of the company’s closure previously announced Integration with Vyome Therapeutics, Inc. And (Y) sixty (60) days after the approval of the shares holder. Ordinary shares (or pre -funded orders) cannot be purchased and accompanying memories except in this general offer, but will be issued separately and will be separated immediately at the release. It is expected that the total revenues of the company, before deducting the employer fees and other display expenses, will be about $ 6.0 million. The show is expected to be closed on February 18 or around 2025, taking into account the usual conditions of closure.

Maxim Group LLC acts as a single recruitment worker in terms of offers.

A registration statement was presented in the S-1 (File No. 333-284362) at the American Securities and Exchange Committee (“SEC”), in its modified form, and announced on February 14, 2025 and the registration statement in the S-1 form, was submitted by Article 462 (B) From the Securities Law of 1933, in its amended form, it was submitted to the Supreme Education Council and became effective upon its presentation on February 14, 2025 (together, “registration statement”). A final bulletin related to offers with SEC will be presented and will be available on SEC on SEC on http://www.sec.gov. The offer is presented only by a bulletin bulletin part of the effective registration statement. Electronic copies of the version leaflet related to this offer can also be obtained, when available, from Maxim Group LLC, 300 Park Avenue, Sixteenth floor, New York, New York 10022, attention: Syndicate Department, by phone on (212) 895-3745 or on Email road on syndicate@maximgrp.com.

This press statement should not constitute an offer for sale or request for an offer to purchase any of the securities described here, and there should not be any sale of these securities in any other state or competence in which this offer, contact or sale illegal will be illegal before registration or rehabilitation under Securities laws in any other state or jurisdiction.

About Lifesciences®
RESHAPE LIFESCINCESS® is the first company for weight loss and metabolism in America, providing an integrated set of proven products and services that manage and treat obesity and metabolic diseases. LAP-PAND® and LAP-PAND® 2.0 Flex systems accredited by FDA and LAP-Pand® 2.0 provides a long-term long-term treatment, which is an alternative to the most engraved surgical stapling procedures such as gastrointestinal removal or stomach removal. The nervous formation system for the treatment of diabetes (previously, previously, the concept of neurological implants of diabetes (DBSN ™)) is a new concept of therapeutic implant that provides electrical nervous format for the neurological branches that do not decrease in the field of sugar in the plasma. Obalon® Balloon is a non -surgical balloon, full of gas -filled gas that is designed to provide long -term weight loss. For more information, please visit www.reshapelifesciences.com.

A safe appearance statement
This press statement may contain aspecting data in the meaning of the 1995 litigation reform law. Actual results can differ financially from those discussed due to the known and unknown risks, uncertainty, and other factors. These aspecting phrases can be identified in general by using words such as “expectation”, “plan”, “expectation”, “can,” May “,” intend “,” Will “,” follow -up, “” the future, “other words A similar meaning and the use of future dates. The factors that can cause actual results are materially disagreeing about those that have been discussed in aspiration data, among other things related to the completion of the presentation and the satisfaction of the usual closure conditions related to the presentation. Fully in the company’s files with the Securities and Exchange Commission, including those factors that have been determined as “risk factors” in the latest annual report on the 10-K and the subsequent quarterly reports on the 10-c. We provide this information as of the date This press statement and we do not face any obligation to update any aspecting data contained in this document as a result of new information, future events, or otherwise, except for what is required under the law.

Communication authorities
Lifesciences:
Paul F. Hiki
President and CEO
949-276-7223
Ir@reshapelifesci.com

Investor relationship connection:
RX Communications Collection
Michael Miller
917-633-6086
mmiller@rxir.com